Patient profiles are representative
and not actual DUPIXENT patients.

Rita’s clinical profile and challenges

  • Experienced 2 exacerbations in the last 12 months requiring OCS prescribed by her PCP
  • Compliant with triple inhaled therapy (LAMA + LABA + ICS)
  • Coughing and fatigue are affecting her work
  • EOS count performed by her pulmonary specialist after most recent appointment:
    200 cells/μL
    • This prompted the pulmonary specialist to review her EHR and found
      EOS=400 cells/μL in the past 12 months*

Explore DUPIXENT data
for a patient like Rita

Up to 34% Reduction in Exacerbations1-3

(PRIMARY ENDPOINT)BOREAS Trial

30% reduction in the annualized rate of moderate or severe exacerbationsa for DUPIXENT + triple therapy (0.78 exacerbations per year [n=468] vs 1.10 for placebo + triple therapy [n=471]; P<0.001)b

NOTUS Trial

34% reduction in the annualized rate of moderate or severe exacerbationsa for DUPIXENT + triple therapy (0.86 exacerbations per year [n=470] vs 1.30 for placebo + triple therapy [n=465]; P<0.001)c

51% of patients reported a clinically meaningful improvement in quality of live scores1-4,*

*as measured by SGRQ

(PRIMARY ENDPOINT)BOREAS Trial

51% of patients reported a clinically meaningful (≥4-point) improvement in SGRQ scores at Week 52 with DUPIXENT + triple therapy vs 43% for placebo + triple therapy (N=939; OR: 1.44; 95% CI: 1.10, 1.89; P=0.009)1,2,d

NOTUS Trial

51% responder rate at Week 52 for subjects treated with DUPIXENT + triple therapy vs 47% for placebo + triple therapy (N=721; OR: 1.16; 95% CI: 0.86, 1.58)1,3

NOTUS results are descriptive. Definitive conclusions cannot be made.

Patients showed improvement in lung function through week 521,e

Change in post-bronchodilator FEV1 from baseline at Week 12 and Week 52 (ITT population; secondary endpoint)1

BOREAS Trial

138 mL numerical improvement for DUPIXENT + triple therapy (n=468) vs 58 mL for placebo + triple therapy
(n=471) at Week 521

NOTUS Trial

127 mL numerical improvement for DUPIXENT + triple therapy (n=362) vs 59 mL for placebo + triple therapy (n=359) at Week 52 (LSM change from baseline, ITT population)1,5

Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.

Significant improvements of similar magnitude were observed in change from baseline in pre-bronchodilator FEV1 at Weeks 12 and 52 in subjects treated with DUPIXENT compared to placebo across the BOREAS and NOTUS trials.

DUPIXENT is the only biologic in COPD that delivered efficacy across all three measures: exacerbation
reduction, lung function improvement, and quality of life improvement1-3

LEARN MORE ABOUT
HOW DUPIXENT
CAN
HELP PATIENTS LIKE RITA

*Rita’s baseline eosinophil count has fluctuated, which is expected as eosinophil levels fluctuate significantly, even hour to hour. 40% of patients in DUPIXENT trials had EOS <300 at randomization, but all patients had EOS ≥300 at screening. Regardless of eosinophil levels at baseline, DUPIXENT reduced patients’ annualized rate of moderate or severe exacerbations. Patients’ eosinophil levels should be checked and results from previous years reviewed for history of elevated eosinophils, as eosinophil levels fluctuate.6-8

aModerate exacerbations were defined as exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were defined as exacerbations that led to hospitalization or an emergency medical care visit or that resulted in death.1-3

bRate ratio vs placebo: 0.71 (95% CI: 0.58, 0.86).1

cRate ratio vs placebo: 0.66 (95% CI: 0.54, 0.82).1

dThe SGRQ is a 50-item questionnaire designed to measure and quantify health status in adult patients with chronic airflow limitation. Higher score indicates greater disease severity.4

eIn the NOTUS trial, patients administered DUPIXENT + triple therapy saw nominal improvement in post-bronchodilator FEV1 of 134 mL at Week 12 and 127 mL at Week 52 (n=362), compared with 67 mL at Week 12 (n=465) and 59 mL at Week 52 (n=359) in patients receiving placebo + triple therapy (LSM change from baseline, ITT population).1,5